ONC — Oncolytics Biotech Cashflow Statement
0.000.00%
Last trade - 00:00- CA$108.60m
- CA$74.12m
Annual cashflow statement for Oncolytics Biotech, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -33.1 | -22.5 | -26.3 | -24.8 | -27.8 |
| Depreciation | |||||
| Non-Cash Items | 14.5 | -0.219 | 4.33 | 0.697 | -2.86 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.8 | 0.21 | -0.908 | 0.391 | 1.76 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -19.9 | -22.1 | -22.4 | -23.4 | -28.4 |
| Capital Expenditures | -0.011 | -0.029 | -0.286 | -0.055 | -0.008 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | — | — | -20.3 | 20.2 |
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.011 | -0.029 | -0.286 | -20.4 | 20.2 |
| Financing Cash Flow Items | 8.13 | 38.3 | 32.9 | 12.6 | 10.3 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 21 | 39.8 | 33 | 12.2 | 32 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.448 | 17.1 | 10 | -29.6 | 23.2 |